Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator (SARM), for Acute Hip Fracture SAN DIEGO, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or...